[177Lu]Lu-TacsBOMB5, [177Lu]Lu-LW01110, and [177Lu]Lu-LW01142 showed significantly higher tumor/pancreas ratios at all five time-points compared with [177Lu]Lu-AMBA, suggesting better biodistribution profiles and lower off-target uptake of our GRPR-targeted ligands. The gene discussed is GRPR; the disease is neoplasm.